Unveiling noradrenaline : insights into cardiac autonomic neuropathy in a type 1 diabetic animal model

Abstract

BACKGROUND: The global surge in Type 1 Diabetes Mellitus (T1DM) cases across age groups has raised concerns about associated cardiovascular risks, warranting a deeper understanding of its complications. Diabetic Cardiovascular Autonomic Neuropathy (DCAN), characterized by cardiovascular system irregularities in diabetic patients, remains inadequately explored, particularly in T1DM. This study aimed to establish a connection between T1DM and the onset of DCAN in an animal model, focusing on the role of noradrenaline as a potential marker.

METHODS: Male Wistar rats were randomly divided into Control and T1DM model groups. The diabetic group received intraperitoneal Streptozotocin injections and remained untreated until DCAN developed. Blood glucose levels and body weight were measured weekly. Vital signs monitoring, and noradrenaline measurements were conducted at specific intervals using non-invasive techniques and ELISA kits to assess the rats' cardiovascular parameters and noradrenaline levels throughout the study period.

RESULTS: Subsequent analysis revealed distinct alterations in blood glucose, body weight, blood pressure, and heart rate in the diabetic group, mirroring clinical symptoms observed in diabetes. Notably, a significant rise in serum noradrenaline levels at week 14 suggested the emergence of DCAN.

DISCUSSION: Findings demonstrate a parallel between T1DM and the development of DCAN, echoing observations in human diabetic patients. Importantly, this study highlights the potential of noradrenaline as an early indicator of DCAN onset. Despite limitations in sample size and duration, these groundbreaking insights pave the way for refining diagnostic strategies and developing targeted therapies for this debilitating complication in diabetic patients.

CONCLUSION: This investigation offers critical insights into the pathophysiology of DCAN in T1DM, emphasizing the urgent need for early detection and management strategies to mitigate associated cardiovascular risks in diabetic individuals.